Satsuma Pharmaceuticals, Inc. (STSA) Stock Analysis
DELISTED 2023
What happened to Satsuma Pharmaceuticals, Inc. (STSA) stock?
Satsuma Pharmaceuticals, Inc. (STSA) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Satsuma Pharmaceuticals, Inc. (STSA) trades at $1.10. Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute migraines. Their lead product candidate, STS101, is in Phase 3 trials. Market cap: $36.5M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for STSA: STSA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates STSA against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
STSA: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Satsuma Pharmaceuticals, Inc. (STSA) Healthcare & Pipeline Overview
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in migraine treatments, with its lead candidate, STS101, undergoing Phase 3 trials. The company utilizes a proprietary dry-powder formulation and nasal delivery device, positioning it within the competitive migraine therapeutics market.
What Is the Investment Thesis for STSA?
Satsuma Pharmaceuticals, Inc. presents a focused investment opportunity within the migraine therapeutics market. The company's lead product candidate, STS101, undergoing Phase 3 trials, targets a significant unmet need for acute migraine treatment. Successful trial outcomes and subsequent regulatory approval could drive substantial revenue growth. Key value drivers include the proprietary dry-powder formulation and nasal delivery device, potentially offering improved efficacy and patient convenience. However, the company's success is contingent on positive clinical trial data and regulatory approvals. The market capitalization is $0.04B, and the beta is 0.10, indicating lower volatility compared to the broader market. Upcoming clinical trial results will be critical in determining the company's future prospects.
Based on FMP financials and quantitative analysis
STSA Key Highlights
STS101 is Satsuma's lead product candidate, currently in Phase 3 clinical trials for acute migraine treatment.
- The company's proprietary dry-powder formulation of dihydroergotamine mesylate (DHE) aims to improve drug delivery and efficacy.
- Satsuma's nasal delivery device offers a convenient and self-administered treatment option for migraine patients.
- The company's market capitalization is $0.04B, reflecting its early-stage development and potential growth opportunities.
- Satsuma Pharmaceuticals was incorporated in 2016, indicating a relatively young company focused on innovation in migraine therapeutics.
Who Are STSA's Competitors?
STSA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STSA's Key Strengths?
Novel drug-device combination for migraine treatment.
- Proprietary dry-powder formulation and nasal delivery device.
- Focus on addressing unmet needs in migraine therapy.
- Experienced management team with expertise in drug development.
What Are STSA's Weaknesses?
Clinical-stage company with no approved products.
- Reliance on a single lead product candidate.
- Limited financial resources compared to larger pharmaceutical companies.
- High risk associated with clinical trials and regulatory approvals.
What Could Drive STSA Stock Higher?
Announcement of topline results from the SUMMIT Phase 3 efficacy trials for STS101.
- Potential FDA submission for STS101 following positive Phase 3 results.
- Continued enrollment and data monitoring in the SUMMIT Phase 3 trials.
What Are the Key Risks for STSA?
Financial-distress signal — its Altman Z-Score of -7.38 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in the SUMMIT Phase 3 efficacy trials.
- Regulatory rejection of STS101 by the FDA.
- Competition from existing and emerging migraine therapies.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for STSA?
- Successful Completion of Phase 3 Trials: The successful completion of the SUMMIT Phase 3 efficacy trials for STS101 represents a significant growth opportunity for Satsuma. Positive trial results would validate the efficacy and safety of the drug-device combination, paving the way for regulatory approval and commercialization. The migraine therapeutics market is substantial, with a significant portion of migraine sufferers seeking more effective and convenient treatment options. A successful launch of STS101 could capture a considerable market share, driving revenue growth and increasing shareholder value.
- Regulatory Approval and Commercialization: Obtaining regulatory approval from the FDA and other regulatory agencies is crucial for Satsuma's growth. Approval would allow the company to commercialize STS101 and generate revenue from sales. The commercialization strategy may involve partnerships with established pharmaceutical companies or building its own sales and marketing infrastructure. The timeline for regulatory approval depends on the clinical trial results and the regulatory review process, but successful approval would unlock significant growth potential.
- Expansion of Product Pipeline: Satsuma can expand its product pipeline by developing additional therapeutic products for migraine and other neurological disorders. This could involve exploring new drug formulations, delivery methods, or therapeutic targets. Expanding the product pipeline would diversify the company's revenue streams and reduce its reliance on a single product. The timeline for developing new products depends on the complexity of the research and development process, but a diversified product pipeline would enhance the company's long-term growth prospects.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical companies, research institutions, or technology providers can accelerate Satsuma's growth. These partnerships can provide access to funding, expertise, or technology that can enhance the development and commercialization of its products. Collaborations can also expand the company's reach and market presence. The timing and nature of these partnerships depend on the specific opportunities that arise, but strategic collaborations can significantly boost Satsuma's growth trajectory.
- Market Expansion and Geographic Reach: Satsuma can expand its market reach by commercializing its products in new geographic regions. This could involve entering international markets through partnerships or establishing its own operations. Expanding into new markets would increase the company's potential customer base and revenue opportunities. The timeline for market expansion depends on the regulatory requirements and market dynamics in each region, but a broader geographic presence would contribute to Satsuma's long-term growth.
What Are STSA's Competitive Advantages?
- Proprietary dry-powder formulation technology.
- Patented nasal delivery device design.
- Clinical trial data demonstrating efficacy and safety.
- Regulatory exclusivity for approved products.
What Does STSA Do?
Satsuma Pharmaceuticals, Inc., established in 2016 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapeutic solutions for the acute treatment of migraines. The company's primary focus is on addressing the unmet needs of migraine sufferers through advanced drug delivery technologies. Satsuma's lead product candidate, STS101, represents a significant advancement in migraine therapy. STS101 is a drug-device combination that utilizes a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), a well-established migraine treatment. The formulation is designed for self-administration using a proprietary pre-filled, single-use nasal delivery device, offering a convenient and potentially more effective method of drug delivery compared to traditional routes. STS101 is currently undergoing SUMMIT Phase 3 efficacy trials to evaluate its safety and efficacy in treating acute migraines. Satsuma aims to provide a rapid-acting and reliable treatment option for migraine patients, potentially improving their quality of life and reducing the burden of this debilitating condition.
What Products and Services Does STSA Offer?
- Develop novel therapeutic products for the acute treatment of migraines.
- Focus on drug-device combination therapies.
- Utilize proprietary dry-powder formulations for improved drug delivery.
- Develop self-administered nasal delivery devices.
- Conduct clinical trials to evaluate the safety and efficacy of their products.
- Seek regulatory approval for their products from the FDA and other agencies.
How Does STSA Make Money?
- Develop and patent novel drug formulations and delivery devices.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval to commercialize products.
- Generate revenue through sales of approved products.
What Industry Does STSA Operate In?
Satsuma Pharmaceuticals operates within the biotechnology sector, specifically targeting the migraine therapeutics market. This market is characterized by a high prevalence of migraine sufferers and a growing demand for more effective and convenient treatment options. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing novel migraine therapies. Satsuma's focus on a proprietary dry-powder formulation and nasal delivery device aims to differentiate it from competitors and capture a share of this expanding market. The migraine therapeutics market is projected to continue growing, driven by increasing awareness and the development of innovative treatments.
Who Are STSA's Key Customers?
- Migraine sufferers seeking acute treatment options.
- Healthcare providers prescribing migraine medications.
- Pharmacies dispensing migraine medications.
- Hospitals and clinics treating migraine patients.
How Satsuma Pharmaceuticals, Inc. Is Valued
Satsuma Pharmaceuticals, Inc. carries a market capitalization of $36.5M, placing it in the micro-cap category.
Company Profile
Satsuma Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO John A. Kollins MBA. STSA has traded publicly since 2019.
Key Financial Metrics
Return on equity for Satsuma Pharmaceuticals, Inc. stands at 125.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 6.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -196.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Satsuma Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.38 places it in the distress zone, a signal of elevated financial risk.
STSA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Satsuma's recent insider buying suggests those in the know see long-term potential, mirroring situations like early Tesla where leadership conviction fueled growth. Community buzz hints at growing excitement for their migraine treatment, potentially shifting market perception. The company's focus on a specific niche could make them an attractive acquisition target, similar to biotech firms acquired for their specialized pipelines. Positive chatter in trading communities indicates retail investors are increasingly optimistic about Satsuma's future prospects.
Bear Case
- Despite insider buying, the overall pharmaceutical market faces regulatory headwinds, reminiscent of the challenges faced by drug developers during the opioid crisis. Community sentiment, while positive in pockets, reveals concerns about competition from established players in the migraine space. Market perception could shift rapidly if clinical trial data disappoints, a risk common in biotech. Bearish voices in social trading circles highlight doubts about Satsuma's ability to scale production and distribution effectively.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
STSA Latest News
No recent news available for STSA.
Leadership: John A. Kollins MBA
CEO
John A. Kollins is the Chief Executive Officer of Satsuma Pharmaceuticals, Inc. He brings extensive experience in the biopharmaceutical industry, with a proven track record of leading and growing companies. His background includes a strong understanding of drug development, commercialization, and corporate strategy. Kollins holds an MBA degree and has held various leadership positions in pharmaceutical and biotechnology companies prior to joining Satsuma Pharmaceuticals. His expertise spans across multiple therapeutic areas, including neurology and pain management.
Track Record: Under John Kollins' leadership, Satsuma Pharmaceuticals has advanced its lead product candidate, STS101, into Phase 3 clinical trials. He has overseen the company's strategic direction, focusing on the development and commercialization of innovative migraine therapies. Kollins has also been instrumental in securing funding and establishing partnerships to support the company's growth. His leadership has been critical in navigating the challenges of clinical development and regulatory approval.
What Investors Ask About Satsuma Pharmaceuticals, Inc. (STSA) — Healthcare
What happened to Satsuma Pharmaceuticals, Inc. (STSA) stock?
Satsuma Pharmaceuticals, Inc. (STSA) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
Can I still buy STSA shares?
No. STSA stopped trading on public markets in June 2023, so the shares are not available through a broker. Anything you see quoted for STSA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before STSA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Satsuma Pharmaceuticals, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Satsuma Pharmaceuticals, Inc. do?
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic products for the acute treatment of migraines. Their lead product candidate, STS101, is a drug-device combination that utilizes a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE) and a self-administered nasal delivery device.
What do analysts say about STSA stock?
Analyst coverage of Satsuma Pharmaceuticals, Inc. is limited due to its market capitalization of $36.5M and clinical-stage status. However, analysts generally focus on the potential of STS101 and the migraine therapeutics market. Key valuation metrics include the potential peak sales of STS101 and the probability of regulatory approval.
What are the main risks for STSA?
The main risks for Satsuma Pharmaceuticals, Inc. include the potential failure to achieve positive results in the SUMMIT Phase 3 efficacy trials for STS101. Negative trial results could significantly impact the company's value and future prospects. Another risk is the potential for regulatory rejection of STS101 by the FDA, which would prevent the company from commercializing its lead product candidate.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market conditions and competitive landscape may evolve.